ADAP

Adaptimmune Therapeutics
ADAP

Overview Fund Trends Analyst Outlook Journalist POV
Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

56 hedge funds and large institutions have $216M invested in Adaptimmune Therapeutics in 2017 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

more first-time investments, than exits

New positions opened: | Existing positions closed:

more funds holding

Funds holding: →

more ownership

Funds ownership: →

more funds holding in top 10

Funds holding in top 10: →

1% less capital invested

Capital invested by funds: $219M → $216M (-$2.84M)

8% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 13

Holders
56
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$1K
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$39M
2
+$1.81M
3
+$1.3M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$846K
5
EIM
Essex Investment Management
Massachusetts
+$679K

Top Sellers

1
-$4.58M
2
-$2.12M
3
-$253K
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$189K
5
PP
Paloma Partners
Connecticut
-$165K
Name Holding Trade Value Shares
Change 		Change in
Stake
26
$453K
27
$449K
28
$441K
29
$295K
30
$287K
31
$258K
32
$242K
33
$226K
34
$182K
35
$161K
36
$159K
37
$156K
38
$128K
39
$108K
40
$108K
41
$91K
42
$89K
43
$71K
44
$48K
45
$46K
46
$42K
47
$32K
48
$27K
49
$16K
50
$9K
1
2
3